OBI Pharma is developing novel therapeutic agents
for patients with unmet medical needs.
- 2024-04-11
Title: OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in various animal models Abstract presentation number: 1893 / Poster number 23/4 PDF LINK Title: In vitro characterization of a novel TROP2-targeting antibody-drug conjugate OBI-992 Abstract presentation number: 3130 / Poster number 21/11 PDF LINK Title:…
- 2024-03-18
Poster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platform. OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC). When evaluated against comparative TROP2 ADCs, OBI-992 demonstrated greater antitumor efficacy, superior PK/PD properties, and…
- 2024-03-12
OBI Pharma is excited to announce that Dr. Ming-Tain Lai, Chief Scientific Officer, has been invited to present an oral presentation at the upcoming 14th World ADC conference in London, United Kingdom. This conference will be held on March 12th-15th, 2024. It united 800+ leading players in the field under one roof, including experts from…